Weill Cornell Genitourinary Cancer Program

04/06/2026

At , Dr. Scott Tagawa talked with Oncology Learning Network about advances in theranostics / targeted radionuclide therapy in solid tumors, including :

Scott Tagawa, MD, discusses the principles and clinical applications of targeted radionuclide therapy in oncology.

04/02/2026

From : Dr. Cora Sternberg shared how new strategies for treating metastatic castration-resistant focused on sequencing, genomics, and earlier use of targeted therapies aim to improve patient outcomes.

New strategies in mCRPC focus on sequencing, genomics and earlier use of targeted therapies to improve outcomes for patients.

03/30/2026

At , Dr. Scott Tagawa spoke about the PSMAddition and how the results could be integrated into the treatment landscape for metastatic hormone-sensitive : https://bit.ly/4sOXDRm (cc: Cancer Network)

Scott Tagawa, MD, MS, FACP, FASCO, evaluated how the rPFS improvement with lutetium 177 could help integrate the treatment into the frontline metastatic HSPC setting.

03/26/2026

From American Society of Clinical Oncology : Dr. Scott Tagawa reviewed outcomes with GU Oncology Now from the BRCAAway comparing two drugs alone and as a combination for metastatic castration-resistant patients with certain gene mutations

Dr. Scott Tagawa discusses an updated analysis from the BRCAAway trial that showed a striking OS advantage for abiraterone plus olaparib.

03/23/2026

Dr. Scott Tagawa and GU research fellow Dr. Baseet Arham discuss recent updates to the tool used to describe the severity of side effects in & what this means for determining maximum treatment doses in the future: https://bit.ly/3P34UOW (cc: GU Oncology Now)

Dr. Abdul Arham discusses the Common Terminology Criteria for Adverse Events and recent changes from v.6 of the criteria.

03/20/2026

New Weill Cornell Medicine published in Nature Portfolio led by Dr. Paraskevi Giannakakou found that a gene called FOXJ1 may drive resistance to taxane during treatment for advanced :

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center.

03/19/2026

Dr. Cora Sternberg was involved with recently published looking at the molecular features of clival metastases, a rare form of advanced associated with cranial nerve palsy:

03/17/2026

In this GU Oncology Now video from American Society of Clinical Oncology , Dr. Scott Tagawa and Sophia Coraci discuss exploring the connection between PSMA PET imaging, tumor biology and disease aggressiveness in patients:

Sophia Coraci, BS, discusses her work on a study that examined the diagnostic performance of SUVmax in patients with treatment-naive prostate cancer.

03/13/2026

At American Society of Clinical Oncology , Dr. Scott Tagawa and NewYork-Presbyterian Hospital fellow Dr. Tobechukwu Okobi talked to GU Oncology Now about patient reported outcomes during and after 225Ac-J591 PSMA therapy for :

Dr. Tobechukwu Joseph Okobi reviews a dose escalation/expansion trial of a prior phase 1 study that demonstrated the efficacy of 225Ac-J591.

02/23/2026

Part 5 of the GU Oncology Now discussion on clonal hematopoiesis in the field of dives into how treatment intensity, timing, and monitoring might limit clonal expansion in select patients. Watch Dr. Scott Tagawa and Dr. Pinkal Desai explain:

The panelists explore how treatment intensity, timing, and monitoring might be optimized to limit clonal expansion.

02/19/2026

Healthcare professionals: Dr. Scott Tagawa is speaking at an adjunct symposium during American Society of Clinical Oncology on 2/27. Register for in-person or virtual participation to learn about the treatment landscape of metastatic hormone-sensitive .

Join us for a dynamic live symposium held adjunct to the 2026 ASCO® Genitourinary Cancers Symposium where two nationally recognized experts will...

02/17/2026

In the next part of the GU Oncology Now discussion on clonal hematopoiesis in the field of , Dr. Scott Tagawa and Dr. Pinkal Desai discuss clinical implications in the era of PSMA-targeted therapies:

This is a 429 error. Try accessing this page directly or wait a few minutes and try again. Everyone has their limits, and we're getting too many requests right now.